Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial.

July 28, 2026| Source: Nature medicine

Group B Streptococcus (GBS) disease is a major cause of infant morbidity and mortality. Capsular polysaccharide conjugate GBS vaccines have been evaluated for decades; however, none is licensed. This phase 1/2 trial evaluated an investigational maternal hexavalent polysaccharide-protein conjugate GBS vaccine (GBS6) in non-pregnant females and pregnant participants and their infants. In stage 1 (conducted in South Africa), healthy non-pregnant participants received GBS6, GBS6 + aluminum phosphate (AlPO 4 ) or placebo; a subset received GBS6 + AlPO 4 booster approximately 2 years later. Stage 2 (conducted in South Africa) maternal dose-finding data were reported previously and are not presented here. In stage 3, healthy pregnant participants from South Africa, the United States and the United Kingdom received GBS6 or placebo (24-36 weeks' gestation). In stage 1, 66 non-pregnant participants received GBS6, GBS6 + AlPO 4 or placebo (n = 22 each); 26 also received GBS6 + AlPO 4 booster. In stage 3, 216 pregnant participants were included (GBS6, n = 108; placebo, n = 108); 209 infants were born to maternal participants (GBS6, n = 104; placebo, n = 105). Primary objectives described GBS6 safety/tolerability profiles. Nearly all reactogenicity events were mild or moderate. Among non-pregnant participants, no serious adverse events (SAEs) or adverse event (AE)-associated withdrawals were reported after vaccination; medically attended adverse events (MAEs) were reported in similar percentages across primary vaccination groups (GBS6 groups = 41-45%; placebo = 41%). Rates of AEs (GBS6 = 75/108 (69%); placebo = 70/108 (65%)), SAEs (GBS6 = 21/108 (19%); placebo = 23/108 (21%)) and delivery outcome frequencies were similar in GBS6 and placebo maternal participants. Most infants were born full-term. Infant AE (GBS6 = 87/104 (84%); placebo = 86/105 (82%)), SAE (GBS6 = 45/104 (43%); placebo = 46/105 (44%)) and MAE (GBS6 = 65/104 (63%); placebo = 66/105 (63%)) frequencies were similar across groups. Two neonatal sepsis-associated deaths occurred (GBS6 = 1; placebo = 1); neither was considered vaccine related. Secondary objectives described immune responses. GBS6 elicited robust immune responses in non-pregnant and pregnant individuals; additionally, serotype-specific quantitative and functional antibody responses were observed in infants whose parent received GBS6. These data support continuing clinical investigation of maternal GBS6 vaccination. ClinicalTrials.gov identifier: NCT03765073 .

Read the original source →

An innervated and vascularized HNSCC-on-a-chip model built on defined and tunable engineered extracellular matrices.

Understanding the tumor microenvironment requires experimental platforms that faithfully recapitulate its key components. Here, we present an innervated and vascularized head and neck squamous cell carcinoma (HNSCC)-on-a-chip platform built with fully defined and tunable engineered extracellular matrices (eECMs). In a stepwise increase of complexity, we first cocultured patient-derived HNSCC cells, cancer-associated fibroblasts, and endothelial cells within tailored eECMs, revealing extracellula

Septin binding restricts Shigella growth and triggers intracellular tolerance.

Pathogen survival relies on their ability to adapt to changing environments, yet how intracellular bacteria tolerate cell-autonomous immunity remains unclear. Septins assemble into cage-like structures around cytoplasmic Shigella targeted by autophagy, but their antibacterial activity was unknown. Using advanced microscopy and cell-free reconstitution, we show that septins polymerize into circumferentially oriented filaments that inhibit bacterial growth. RNA-sequencing reveals that septin bindi

DCAF6 reprograms TGF-β responses through TRIM33 destruction.

TGF-β signaling plays a pivotal role in regulating numerous cellular processes, primarily through the Smad-dependent pathway. Disruptions of the pathway are associated with developmental disorders and life-threatening diseases, such as cancer. It has been reported that TRIM33 inactivates Smad4 signaling and also drives its own signaling responses. However, the mechanism controlling TRIM33 activity has remained unclear. In this study, we identify DCAF6 as a previously unrecognized ubiquitin

Stimulated protein degradation to promote mitochondrial function and neuronal survival.

Targeted protein degradation is a promising modality to treat cancer or inflammation, but whether it can provide a similar benefit for disorders caused by pervasive protein dysregulation is unclear. We describe stimulated protein degradation (SPD) as a strategy that leverages agonists of stress-responsive E3 ubiquitin ligases to simultaneously eliminate multiple pathogenic factors. Specifically, we show that activators of the reductive stress response E3 CUL2 FEM1B boost degradation of multiple

Spatial coordination in the codevelopment of the human urogenital system during organogenesis.

The human urogenital system originates from a common embryonic domain, yet the mechanisms guiding its spatiotemporal coordination remain understudied. Here, we combined high-resolution spatial transcriptomics with single-cell multiomics to profile human embryos from Carnegie stages 15 to 23, capturing the codevelopmental dynamics of the urogenital system. We revealed mesonephros- and adrenal primordium-derived signals that promote gonadal specification and enable efficient in vitro generation of